Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $1.99 billion. The enterprise value is $2.00 billion.
Important Dates
The last earnings date was Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.29 billion shares outstanding. The number of shares has increased by 14.51% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.29B |
| Shares Change (YoY) | +14.51% |
| Shares Change (QoQ) | +1.47% |
| Owned by Insiders (%) | 34.90% |
| Owned by Institutions (%) | 27.28% |
| Float | 824.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 118.46 |
| PS Ratio | 30.51 |
| Forward PS | 11.45 |
| PB Ratio | 3.47 |
| P/TBV Ratio | 339.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 30.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.58 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.17 |
Financial Efficiency
Return on equity (ROE) is -18.22% and return on invested capital (ROIC) is -6.82%.
| Return on Equity (ROE) | -18.22% |
| Return on Assets (ROA) | -6.16% |
| Return on Invested Capital (ROIC) | -6.82% |
| Return on Capital Employed (ROCE) | -10.82% |
| Weighted Average Cost of Capital (WACC) | 8.88% |
| Revenue Per Employee | $807,210 |
| Profits Per Employee | -$1.17M |
| Employee Count | 81 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 3.86 |
Taxes
In the past 12 months, Mesoblast has paid $563,000 in taxes.
| Income Tax | 563,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.64% in the last 52 weeks. The beta is 0.79, so Mesoblast's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +40.64% |
| 50-Day Moving Average | 15.08 |
| 200-Day Moving Average | 16.31 |
| Relative Strength Index (RSI) | 54.65 |
| Average Volume (20 Days) | 149,589 |
Short Selling Information
The latest short interest is 2.94 million, so 3.12% of the outstanding shares have been sold short.
| Short Interest | 2.94M |
| Short Previous Month | 2.91M |
| Short % of Shares Out | 3.12% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 16.96 |
Income Statement
In the last 12 months, Mesoblast had revenue of $65.38 million and -$94.37 million in losses. Loss per share was -$0.07.
| Revenue | 65.38M |
| Gross Profit | -23.23M |
| Operating Income | -70.78M |
| Pretax Income | -93.81M |
| Net Income | -94.37M |
| EBITDA | -64.34M |
| EBIT | -70.78M |
| Loss Per Share | -$0.07 |
Full Income StatementBalance Sheet
The company has $129.98 million in cash and $135.14 million in debt, with a net cash position of -$5.17 million or -$0.00 per share.
| Cash & Cash Equivalents | 129.98M |
| Total Debt | 135.14M |
| Net Cash | -5.17M |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 574.68M |
| Book Value Per Share | 0.45 |
| Working Capital | 74.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.64 million and capital expenditures -$996,000, giving a free cash flow of -$60.64 million.
| Operating Cash Flow | -59.64M |
| Capital Expenditures | -996,000 |
| Depreciation & Amortization | 6.44M |
| Net Borrowing | -5.31M |
| Free Cash Flow | -60.64M |
| FCF Per Share | -$0.05 |
Full Cash Flow StatementMargins
Gross margin is -35.53%, with operating and profit margins of -108.25% and -144.33%.
| Gross Margin | -35.53% |
| Operating Margin | -108.25% |
| Pretax Margin | -143.47% |
| Profit Margin | -144.33% |
| EBITDA Margin | -98.40% |
| EBIT Margin | -108.25% |
| FCF Margin | n/a |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.51% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.73% |
| FCF Yield | -3.04% |
Analyst Forecast
The average price target for Mesoblast is $35.00, which is 127.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.00 |
| Price Target Difference | 127.27% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 117.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 10, 2024. It was a reverse split with a ratio of 1:2.
| Last Split Date | Jan 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Mesoblast has an Altman Z-Score of 3.45 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.45 |
| Piotroski F-Score | 5 |
